Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITM-51
- Development stage
- Unknown
- Lead developer
- ITM Isotope Technologies Munich
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ITM-51 is a targeted radiopharmaceutical developed by Isotope Technologies Munich (ITM) for the treatment of folate receptor alpha (FRα)-expressing cancers, specifically ovarian cancer. It consists of a high-affinity ligand targeting FRα, labeled with the beta-emitting radioisotope lutetium-177 (177Lu). FRα is highly overexpressed in various solid tumors, including over 80% of ovarian cancers, while having limited expression in normal tissues. Upon binding to the receptor, the complex is internalized, allowing the 177Lu to deliver precise, localized radiation that causes double-stranded DNA breaks and subsequent cell death in the tumor cells. The drug utilizes ITM's proprietary no-carrier-added (n.c.a.) lutetium-177 to ensure high specific activity and purity.
- Other names
- Lu-177-FRαlutetium (177Lu) folate receptor alpha-targeting radiopharmaceutical
02
Targets
FOLR1 (FRα)
Beyond the preview
Go deeper on ITM-51.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITM-51.